Cardior Pharmaceuticals Is A Clinical Stage Biopharmaceutical Company Based In Hannovergermanyfocused On Developing Rna Based Therapeutics For Cardiovascular Diseasesparticularly Heart Failurefounded In 2016The Company Aims To Address The Root Causes Of Cardiac Dysfunction Through Innovative Non Coding Rnancrnatherapiescardior Has Raised $92 3 Million In Fundingincluding A Significant $76 Million Series B Roundwith Notable Investors Such As Eqt Life Sciences And Bristol Myers Squibb The Company S Lead Therapeutic Candidatecdr132Lis Currently Undergoing The Hf Revert Phase 2 Clinical Study For Heart Failure Patients Following Myocardial Infarctioncardior S Research Emphasizes The Use Of Ncrnas To Counteract Pathological Processes In Cardiac Diseasespositioning It As A Pioneer In Precision Therapieswith The Recent Announcement Of Novo Nordisk S Plans To Acquire Cardiorthe Company Is Set To Enhance Its Clinical Development And Expand Its Rna Based Platform To Meet The Needs Of Patients With Chronic Cardiovascular Diseases Globally
